Masks in healthcare workers:
- Surgical masks and respirators (N95) appear similar in preventing viral infections, with statistically different lower infection rates (~1-2%).
- Cloth masks are poorer than surgical (with ~2% RTI x4 wks).
- No RCTs examined transmission to others or COVID-19.
- Masks just one-part PPE and transmission precautions.

Drug Treatment
Without further evidence, hydroxychloroquine is not appropriate for patients with COVID-19 in primary care. A number of recent trials/studies show an increased risk of side effects and QT prolongation especially at higher doses. RCTs are ongoing and hopefully they will provide more insight into the benefit/harm of this empiric treatment.

Clinical Factors
- Cough, fever and dyspnea are the most common symptoms of COVID-19.
- At least 80% of cases are clinically mild, ~10% are hospitalized and 25% of admitted patients require intensive care.
- Mortality risk factors include long-term care residents, age >65, co-morbid illnesses, and COVID-19 associated cardiac injury.

Testing
Studies of clinical PCR sensitivity are limited and vary widely for many reasons. Even if test sensitivity ranged between 50-90%, patients with low pretest probability (example 10%) would have at worst a 5% false negative rate.

Miscellaneous
There is no reliable evidence that NSAIDs, ACE inhibitors or ARBs increase the risk of COVID-19 or affect disease severity/mortality from COVID-19.

Masks in the community may reduce transmission of viral RTI (from 2 RCTs). If community risk was ~25% over 6 weeks, masks could decrease that to ~19%. No COVID-19 research, many studies examined others risk once someone was sick, and the overall certainty of evidence is low. Any mask use should be combined with social distancing and other preventive strategies.

Transmission of COVID-19 can occur in people who are currently asymptomatic (including those who will remain asymptomatic and those who are early and not symptomatic yet). Case reports suggest this occurs in 6-13% of cases, although modelling suggests this might be higher. ~50% of carriers are asymptomatic when an entire population is tested.

Unfortunately, no specific technique, including the Roth Score, reliably assures dyspneic patients are safe. No studies assessed dyspnea in COVID-19 patients. Clinicians are encouraged to use available tools (BMJ Virtual Assessment tool) and have patients assessed in-person if any concerns.

To date, no published RCTs have demonstrated benefit of treating COVID-19 patients with remdesivir, lopinavir–ritonavir or oseltamivir. One interim analysis of remdesivir suggests improved time to recovery. Full publication of studies and ongoing trials will help to answer this question.

While IGM and IGG antibodies (serology) may tell individuals recent or past exposure – it is unclear whether antibodies confer immunity to subsequent infection. Accuracy of antibody testing likely requires validation in large number of infected and non-infected individuals.

~50% of carriers are asymptomatic when an entire population is tested.